13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • IMCgp100-202

    Acronym: 

    IMCgp100-202

    ACTRN/NCT /ethics: 

    Scientific title: 

    A Phase II Randomized, open-label, Multi-centre study of the safety and efficacy of IMCgp100 compared with Investigator choice in HLA-A*0201 positive patients with previously untreated advanced uveal melanoma.

    Summary of trial and patient characteristics

    Cancer Type Head and Neck, Melanoma & other skin
    Trial Type Treatment
    Phase Phase II Tumour Stream Uveal Melanoma
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Head and Neck, Melanoma & other skin
    Trial Type Treatment
    Phase Phase II
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Uveal Melanoma
    Cancer Stage Locally Recurrent or Locally Advanced
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    A phase II randomized, open-label, multi-centre study of the safety and efficacy of IMCgp100 compared with Investigator choice in HLA-A*0201 positive patients with previously untreated advanced uveal melanoma.

    Lay Summary

    A Phase II Randomized, open-label, Multi-centre study of the safety and efficacy of IMCgp100 compared with Investigator choice in HLA-A*0201 positive patients with previously untreated advanced uveal melanoma.

    Sponsor / Cooperative group

    Immunocore

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Royal Adelaide Hospital Anne Milton anne.milton@sa.gov.au 08 7074 2342 Brown Recruiting